NS Partners Ltd Grows Stake in Becton Dickinson and Co (BDX)

NS Partners Ltd lifted its stake in shares of Becton Dickinson and Co (NYSE:BDX) by 0.7% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 61,772 shares of the medical instruments supplier’s stock after purchasing an additional 421 shares during the period. Becton Dickinson and comprises 1.5% of NS Partners Ltd’s investment portfolio, making the stock its 20th biggest position. NS Partners Ltd’s holdings in Becton Dickinson and were worth $16,122,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Monarch Capital Management Inc. acquired a new position in shares of Becton Dickinson and in the 3rd quarter worth approximately $255,000. King Luther Capital Management Corp lifted its holdings in shares of Becton Dickinson and by 54.8% in the 3rd quarter. King Luther Capital Management Corp now owns 64,114 shares of the medical instruments supplier’s stock worth $16,734,000 after acquiring an additional 22,690 shares during the last quarter. Tocqueville Asset Management L.P. lifted its holdings in shares of Becton Dickinson and by 1.0% in the 3rd quarter. Tocqueville Asset Management L.P. now owns 22,151 shares of the medical instruments supplier’s stock worth $5,782,000 after acquiring an additional 215 shares during the last quarter. Utah Retirement Systems lifted its holdings in shares of Becton Dickinson and by 0.6% in the 3rd quarter. Utah Retirement Systems now owns 49,343 shares of the medical instruments supplier’s stock worth $12,879,000 after acquiring an additional 300 shares during the last quarter. Finally, Connors Investor Services Inc. lifted its holdings in shares of Becton Dickinson and by 2.7% in the 3rd quarter. Connors Investor Services Inc. now owns 37,263 shares of the medical instruments supplier’s stock worth $9,726,000 after acquiring an additional 980 shares during the last quarter. 85.19% of the stock is owned by institutional investors.

Shares of NYSE:BDX traded down $5.70 during trading hours on Thursday, reaching $239.22. The stock had a trading volume of 20,529 shares, compared to its average volume of 1,139,136. Becton Dickinson and Co has a 1 year low of $209.91 and a 1 year high of $265.87. The company has a current ratio of 1.03, a quick ratio of 0.69 and a debt-to-equity ratio of 0.90. The company has a market cap of $65.70 billion, a PE ratio of 21.68, a P/E/G ratio of 1.69 and a beta of 1.21.



Becton Dickinson and (NYSE:BDX) last posted its earnings results on Tuesday, November 6th. The medical instruments supplier reported $2.93 EPS for the quarter, meeting the Zacks’ consensus estimate of $2.93. The firm had revenue of $4.40 billion for the quarter, compared to the consensus estimate of $4.36 billion. Becton Dickinson and had a net margin of 1.47% and a return on equity of 13.88%. The company’s revenue was up 39.0% on a year-over-year basis. During the same period last year, the firm posted $2.40 EPS. As a group, equities research analysts expect that Becton Dickinson and Co will post 12.1 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Monday, December 31st. Investors of record on Monday, December 10th will be given a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a dividend yield of 1.29%. This is an increase from Becton Dickinson and’s previous quarterly dividend of $0.75. The ex-dividend date is Friday, December 7th. Becton Dickinson and’s dividend payout ratio (DPR) is 27.25%.

A number of research firms have issued reports on BDX. Morgan Stanley increased their target price on shares of Becton Dickinson and from $250.00 to $280.00 and gave the stock an “equal weight” rating in a report on Thursday, October 4th. Wells Fargo & Co increased their target price on shares of Becton Dickinson and from $275.00 to $290.00 and gave the stock an “outperform” rating in a report on Thursday, September 6th. They noted that the move was a valuation call. Citigroup increased their target price on shares of Becton Dickinson and from $274.00 to $283.00 and gave the stock a “buy” rating in a report on Wednesday, August 8th. UBS Group began coverage on shares of Becton Dickinson and in a report on Tuesday, November 27th. They set a “neutral” rating and a $260.00 target price on the stock. Finally, Piper Jaffray Companies reduced their target price on shares of Becton Dickinson and to $250.00 and set an “overweight” rating on the stock in a report on Tuesday, November 6th. Six equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $254.20.

In related news, EVP James W. Borzi sold 5,887 shares of the stock in a transaction on Friday, November 30th. The shares were sold at an average price of $252.37, for a total value of $1,485,702.19. Following the transaction, the executive vice president now directly owns 6,013 shares of the company’s stock, valued at approximately $1,517,500.81. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Thomas E. Polen, Jr. sold 5,243 shares of the stock in a transaction on Monday, November 19th. The shares were sold at an average price of $243.86, for a total transaction of $1,278,557.98. The disclosure for this sale can be found here. Insiders sold a total of 81,795 shares of company stock worth $19,571,318 over the last ninety days. Insiders own 1.00% of the company’s stock.

WARNING: This piece was first published by Dakota Financial News and is the property of of Dakota Financial News. If you are viewing this piece on another site, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://dakotafinancialnews.com/2018/12/06/ns-partners-ltd-grows-stake-in-becton-dickinson-and-co-bdx.html.

Becton Dickinson and Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Featured Article: Systematic Risk

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply